BASF bids €664m for omega-3 company


BASF is to spend €664 million (£530 million) to buy Norwegian firm Pronova BioPharma, which specialises in omega-3 fatty acids. It has the backing of the Pronova board and shareholders representing 60% of the company, including private equity fund Herkules, which owns a 50% stake.

Pronova makes active pharmaceutical ingredients based on omega-3 fatty acids that are used to treat cardiovascular conditions. It also makes dietary supplements.

BASF says that omega-3 fatty acids represent a growing market. The company gained a significant stake in the market through its €3.1 billion purchase of german speciality chemical company Cognis in 2010. It strengthened its position in May this year when it bought UK firm Equateq.

Pronova employs 300 people and makes annual sales of about NOK1.7 billion (£180 million).


Related Content

BASF ups Pronova bid

16 January 2013 Business

news image

Pronova BioPharma specialises in omega-3 fatty acids

BASF to cut 260 jobs in nutrition and health

1 May 2014 Business

news image

Firm to sell Norwegian site and shift focus towards Asia

Most Read

Better batteries with pure lithium anodes

28 July 2014 Research

news image

Protective carbon nanosphere coating overcomes lithium problems, pointing the way to improved capacity

Takeover battle pushes Allergan to cut R&D jobs

28 July 2014 Business

news image

Besieged by serially acquisitive Valeant, the Botox maker will lay off 1500 staff to propel earnings growth

Most Commented

Isoamyl acetate

30 July 2014 Podcast | Compounds

news image

It makes a sweet banana-flavoured treat, but can ruin home brewed beer; Jenna Bilbrey introduces isoamyl acetate

Relativity behind mercury's liquidity

21 June 2013 Research

news image

First evidence that relativistic effects are indeed responsible for mercury's low melting point